| 1 | alone | 27,915 |
| 2 | and/ | 55 |
| 3 | peg-3350 | 17 |
| 4 | diolamine | 16 |
| 5 | 3350+e | 15 |
| 6 | isethionate | 14 |
| 7 | whitei | 11 |
| 8 | placarbil | 9 |
| 9 | system® | 9 |
| 10 | 525797 | 8 |
| 11 | formigenes | 6 |
| 12 | 12791 | 5 |
| 13 | 57033 | 5 |
| 14 | lactantes | 5 |
| 15 | 0.5mg/d | 4 |
| 16 | 60263 | 4 |
| 17 | 60264 | 4 |
| 18 | alone.there | 4 |
| 19 | belangeri | 4 |
| 20 | pl-20 | 4 |
| 21 | postmenopausally | 4 |
| 22 | 1201081 | 3 |
| 23 | 8x/day | 3 |
| 24 | accion | 3 |
| 25 | cgp53353 | 3 |
| 26 | hemocytometry | 3 |
| 27 | plus-j | 3 |
| 28 | poly-l-lysines | 3 |
| 29 | s.r.l. | 3 |
| 30 | ≤20/40 | 3 |
| 31 | 1:0.5 | 2 |
| 32 | 2b-4b | 2 |
| 33 | 2r→3r | 2 |
| 34 | 5823 | 2 |
| 35 | 8-sulfophenyltheophylline | 2 |
| 36 | aml/arbs | 2 |
| 37 | andplacebo | 2 |
| 38 | based-regimen | 2 |
| 39 | bio-oss® | 2 |
| 40 | bladder-irrigation | 2 |
| 41 | curantur | 2 |
| 42 | deo | 2 |
| 43 | dyadically | 2 |
| 44 | equiv./l | 2 |
| 45 | ga-bao | 2 |
| 46 | guided-therapy | 2 |
| 47 | high-igg | 2 |
| 48 | ic.04-12 | 2 |
| 49 | inter-changeably | 2 |
| 50 | intraarticulary | 2 |
| 51 | nxy-058 | 2 |
| 52 | orange® | 2 |
| 53 | p42a | 2 |
| 54 | parodontocid | 2 |
| 55 | pgp-4008 | 2 |
| 56 | q15l | 2 |
| 57 | self-mixed | 2 |
| 58 | time/resident/day | 2 |
| 59 | wideness | 2 |
| 60 | xk1 | 2 |
| 61 | +42.9 | 1 |
| 62 | +beta | 1 |
| 63 | +guaiphenesin | 1 |
| 64 | -bg-csf | 1 |
| 65 | -ifna-2a | 1 |
| 66 | 0.4-ms | 1 |
| 67 | 0.5mg/day | 1 |
| 68 | 0/85 | 1 |
| 69 | 1,4-diethynylphenyl | 1 |
| 70 | 10/10- | 1 |
| 71 | 10/20-mg | 1 |
| 72 | 10/40mg | 1 |
| 73 | 100mg/m² | 1 |
| 74 | 122/282 | 1 |
| 75 | 12457-1 | 1 |
| 76 | 12457-2 | 1 |
| 77 | 124:2422-2426 | 1 |
| 78 | 129/704 | 1 |
| 79 | 18μg | 1 |
| 80 | 1x3g | 1 |
| 81 | 1½- | 1 |
| 82 | 1×week | 1 |
| 83 | 2,4-diacyl-2,3-dihydrofuran | 1 |
| 84 | 2-aminoadenine | 1 |
| 85 | 2-aminoethyldiphenylborinate | 1 |
| 86 | 2-chloroethyl-ethylsulfide | 1 |
| 87 | 2.32-2.87 | 1 |
| 88 | 2.38-2.56 | 1 |
| 89 | 2.5/80 | 1 |
| 90 | 20+/-7.9 | 1 |
| 91 | 20-nucleotides | 1 |
| 92 | 24i.u | 1 |
| 93 | 250mg/d | 1 |
| 94 | 282-383 | 1 |
| 95 | 2b/rbv | 1 |
| 96 | 3-hydroxy-2-methylpentanal | 1 |
| 97 | 3-sambubioside | 1 |
| 98 | 3.75-5.33 | 1 |
| 99 | 3000mg | 1 |
| 100 | 301a | 1 |
| 101 | 32.6gl | 1 |
| 102 | 36/126 | 1 |
| 103 | 4-amino- | 1 |
| 104 | 4.07-5.22 | 1 |
| 105 | 5,7-dihydroxyflavanone | 1 |
| 106 | 5-aza-2'-deoxycytodine | 1 |
| 107 | 5-malonyl-1,3,4-tricaffeoylquinic | 1 |
| 108 | 500u | 1 |
| 109 | 521873 | 1 |
| 110 | 55/68 | 1 |
| 111 | 58.940 | 1 |
| 112 | 5mgday | 1 |
| 113 | 6/319 | 1 |
| 114 | 64-gy | 1 |
| 115 | 68843 | 1 |
| 116 | 7-glucuronide | 1 |
| 117 | 7.0l/minute | 1 |
| 118 | 72000 | 1 |
| 119 | 75/18.5/200 | 1 |
| 120 | 7npvc | 1 |
| 121 | 8.8l/minute | 1 |
| 122 | 9,179 | 1 |
| 123 | =2,6-dimethylphenyl | 1 |
| 124 | abluminal/distal | 1 |
| 125 | ac-kaltghlee-am | 1 |
| 126 | ac-n-buoh-ef- | 1 |
| 127 | achp | 1 |
| 128 | action- | 1 |
| 129 | acupunctrure | 1 |
| 130 | after1 | 1 |
| 131 | alkaline-activation | 1 |
| 132 | alpha-calcidol | 1 |
| 133 | ambulatoire | 1 |
| 134 | aminohexylgeldanamycin | 1 |
| 135 | andsaponins | 1 |
| 136 | anodyne® | 1 |
| 137 | anti-xa-lmwh | 1 |
| 138 | arg-76 | 1 |
| 139 | asp433 | 1 |
| 140 | atpb-rbcl | 1 |
| 141 | aua1 | 1 |
| 142 | augmented-wave | 1 |
| 143 | available-statins | 1 |
| 144 | azatadine | 1 |
| 145 | basistropfen | 1 |
| 146 | bmpo | 1 |
| 147 | boceprevir- | 1 |
| 148 | caf1 | 1 |
| 149 | casearins | 1 |
| 150 | cba- | 1 |
| 151 | cholesytramine | 1 |
| 152 | cispcis-diamminedichloroplatinum | 1 |
| 153 | citrate-midazolam | 1 |
| 154 | cl/ml | 1 |
| 155 | clplhis₆ | 1 |
| 156 | cmfpv | 1 |
| 157 | cocaine-based | 1 |
| 158 | comparisions | 1 |
| 159 | con-only | 1 |
| 160 | coparticipants | 1 |
| 161 | copt1- | 1 |
| 162 | corecontrol® | 1 |
| 163 | critiquing/planning | 1 |
| 164 | crm-carbohydrate | 1 |
| 165 | csa-rad-mp | 1 |
| 166 | cyclodestructive | 1 |
| 167 | cystis | 1 |
| 168 | d4t/3tc- | 1 |
| 169 | daunorubicin/ara-c | 1 |
| 170 | dbs/medications | 1 |
| 171 | declizumab | 1 |
| 172 | dehydrobutyrine | 1 |
| 173 | dermatophagasp | 1 |
| 174 | des-sevo | 1 |
| 175 | dextro-1-methyl-tryptophan | 1 |
| 176 | dic8- | 1 |
| 177 | differentiation/mineralization | 1 |
| 178 | dihydropiridine-preparations | 1 |
| 179 | discontinuation/interruption | 1 |
| 180 | disparting | 1 |
| 181 | dnase/rnase | 1 |
| 182 | docetaxel/doxorubicin | 1 |
| 183 | docetaxel/estramustine | 1 |
| 184 | drophammer | 1 |
| 185 | edisilate | 1 |
| 186 | elvitegravir/ritonavir | 1 |
| 187 | en77 | 1 |
| 188 | enhancer1 | 1 |
| 189 | esi-negative-ms | 1 |
| 190 | ethinilestradiol | 1 |
| 191 | ethylmethnesulphonate | 1 |
| 192 | extraarticularly | 1 |
| 193 | f-k | 1 |
| 194 | f38 | 1 |
| 195 | fadh | 1 |
| 196 | favipiravir | 1 |
| 197 | ferumoxtyol | 1 |
| 198 | fluoexetine | 1 |
| 199 | folfiri.3 | 1 |
| 200 | formingenes | 1 |
| 201 | fst-ul | 1 |
| 202 | ftc/zidovudine/efavirenz | 1 |
| 203 | gartner | 1 |
| 204 | gelatin- | 1 |
| 205 | gentacicol | 1 |
| 206 | gii.13 | 1 |
| 207 | gmfad7-1 | 1 |
| 208 | gpo® | 1 |
| 209 | gramine | 1 |
| 210 | group-£2,171 | 1 |
| 211 | group=76 | 1 |
| 212 | gsk4716 | 1 |
| 213 | hib-specific | 1 |
| 214 | hindfoot-ankle | 1 |
| 215 | hla-b*44:02g | 1 |
| 216 | hyperuremia | 1 |
| 217 | hypo/hyperglycemia-mitigation | 1 |
| 218 | ii-antialdosterones | 1 |
| 219 | immunolymphoscintigraphy | 1 |
| 220 | immunosuppresant | 1 |
| 221 | implicity | 1 |
| 222 | inamd | 1 |
| 223 | inattentively | 1 |
| 224 | inclusive/parallel | 1 |
| 225 | indistinctively | 1 |
| 226 | initiated.3 | 1 |
| 227 | initiation≥10ml/min/1.73m | 1 |
| 228 | insigs | 1 |
| 229 | instruction-a | 1 |
| 230 | internal/autonomous | 1 |
| 231 | intrapartum- | 1 |
| 232 | intratumorly | 1 |
| 233 | iomri-guided | 1 |
| 234 | isotonic- | 1 |
| 235 | kisspeptins | 1 |
| 236 | krabok | 1 |
| 237 | laba/lama/ics | 1 |
| 238 | laryngoscopy-guided | 1 |
| 239 | layer-3 | 1 |
| 240 | levo-adrenaline | 1 |
| 241 | lipofacton | 1 |
| 242 | lm- | 1 |
| 243 | loratadine/montelukast | 1 |
| 244 | lsa2l2-type | 1 |
| 245 | macushield | 1 |
| 246 | medium-acting | 1 |
| 247 | merbarone | 1 |
| 248 | mesostable | 1 |
| 249 | methanethiosulfonate-ethylammonium | 1 |
| 250 | mg-aspartate-hydrochloride | 1 |
| 251 | misadministrations | 1 |
| 252 | misconceptions/misunderstandings | 1 |
| 253 | motor-level | 1 |
| 254 | mscbt | 1 |
| 255 | n-acetyl-l-carnitine | 1 |
| 256 | negative-sad | 1 |
| 257 | no-pv | 1 |
| 258 | no-wup | 1 |
| 259 | no711 | 1 |
| 260 | non-complaint | 1 |
| 261 | non-dipper-type | 1 |
| 262 | non-teacher | 1 |
| 263 | nonsense/splicing | 1 |
| 264 | nr1a/nr2a | 1 |
| 265 | nurse-peer | 1 |
| 266 | obese-resistant | 1 |
| 267 | omstreken | 1 |
| 268 | opbe | 1 |
| 269 | options-extraction | 1 |
| 270 | overdraw | 1 |
| 271 | p-cymene/β-cyclodextrin | 1 |
| 272 | pagaptanbib | 1 |
| 273 | parvastatin | 1 |
| 274 | pentafluorophenylhydrazine | 1 |
| 275 | perfluoroalkoxy | 1 |
| 276 | perfusion-cooling | 1 |
| 277 | phenylglycoside | 1 |
| 278 | placeo | 1 |
| 279 | polyhexamethylene-biguanide | 1 |
| 280 | polystyrene-co-divinylbenzene | 1 |
| 281 | porpouses | 1 |
| 282 | processibility | 1 |
| 283 | propofol/fentanyl/dexmedetomidine | 1 |
| 284 | prp-augmented | 1 |
| 285 | pulsatile- | 1 |
| 286 | pursuit-direction | 1 |
| 287 | q-8h | 1 |
| 288 | quercetin-3-o-β-d-glucopyranosil | 1 |
| 289 | r-467 | 1 |
| 290 | redita | 1 |
| 291 | remifentanil-atropine | 1 |
| 292 | repinotan | 1 |
| 293 | retard® | 1 |
| 294 | riba-positive | 1 |
| 295 | risedronate- | 1 |
| 296 | rituximab-chop | 1 |
| 297 | rm+sm | 1 |
| 298 | rr1.10 | 1 |
| 299 | score-original | 1 |
| 300 | single-ζ | 1 |
| 301 | siramesine | 1 |
| 302 | sodium-diatrizoate | 1 |
| 303 | spheroidene/spheroidenone | 1 |
| 304 | spico | 1 |
| 305 | stami | 1 |
| 306 | study-05 | 1 |
| 307 | study.it | 1 |
| 308 | succinate/glutamate | 1 |
| 309 | survey/enquete | 1 |
| 310 | system1 | 1 |
| 311 | technology™ | 1 |
| 312 | tg1306/1r | 1 |
| 313 | thio-barbituric-acid-reacting-substances | 1 |
| 314 | thiobarbituric-acid-reactive-substances | 1 |
| 315 | threat-alleviating | 1 |
| 316 | thu | 1 |
| 317 | til/il-2 | 1 |
| 318 | time-rtt | 1 |
| 319 | tinture | 1 |
| 320 | tnf-α-inhibitors | 1 |
| 321 | tpbp | 1 |
| 322 | treated-aparasitaemic | 1 |
| 323 | treated-parasitaemic | 1 |
| 324 | twice/year | 1 |
| 325 | un-supplemented | 1 |
| 326 | under-perceivers | 1 |
| 327 | ura3 | 1 |
| 328 | vancomycin/cefepime | 1 |
| 329 | vri-iv | 1 |
| 330 | wg-rich | 1 |
| 331 | wheat-barley-rye- | 1 |
| 332 | whytei | 1 |
| 333 | will:1 | 1 |
| 334 | work-package | 1 |
| 335 | work-they | 1 |
| 336 | xbk1 | 1 |
| 337 | xefocame | 1 |
| 338 | y-690 | 1 |
| 339 | yfh1-isu | 1 |
| 340 | yo8 | 1 |
| 341 | z-asp-ch | 1 |
| 342 | €18,957 | 1 |
| 343 | €3636 | 1 |
| 344 | ≤30min | 1 |
| 345 | ≥1.020 | 1 |
| 1 | +42.9 | 1 |
| 2 | +beta | 1 |
| 3 | +guaiphenesin | 1 |
| 4 | -bg-csf | 1 |
| 5 | -ifna-2a | 1 |
| 6 | 0.4-ms | 1 |
| 7 | 0.5mg/d | 4 |
| 8 | 0.5mg/day | 1 |
| 9 | 0/85 | 1 |
| 10 | 1,4-diethynylphenyl | 1 |
| 11 | 10/10- | 1 |
| 12 | 10/20-mg | 1 |
| 13 | 10/40mg | 1 |
| 14 | 100mg/m² | 1 |
| 15 | 1201081 | 3 |
| 16 | 122/282 | 1 |
| 17 | 12457-1 | 1 |
| 18 | 12457-2 | 1 |
| 19 | 124:2422-2426 | 1 |
| 20 | 12791 | 5 |
| 21 | 129/704 | 1 |
| 22 | 18μg | 1 |
| 23 | 1:0.5 | 2 |
| 24 | 1x3g | 1 |
| 25 | 1½- | 1 |
| 26 | 1×week | 1 |
| 27 | 2,4-diacyl-2,3-dihydrofuran | 1 |
| 28 | 2-aminoadenine | 1 |
| 29 | 2-aminoethyldiphenylborinate | 1 |
| 30 | 2-chloroethyl-ethylsulfide | 1 |
| 31 | 2.32-2.87 | 1 |
| 32 | 2.38-2.56 | 1 |
| 33 | 2.5/80 | 1 |
| 34 | 20+/-7.9 | 1 |
| 35 | 20-nucleotides | 1 |
| 36 | 24i.u | 1 |
| 37 | 250mg/d | 1 |
| 38 | 282-383 | 1 |
| 39 | 2b-4b | 2 |
| 40 | 2b/rbv | 1 |
| 41 | 2r→3r | 2 |
| 42 | 3-hydroxy-2-methylpentanal | 1 |
| 43 | 3-sambubioside | 1 |
| 44 | 3.75-5.33 | 1 |
| 45 | 3000mg | 1 |
| 46 | 301a | 1 |
| 47 | 32.6gl | 1 |
| 48 | 3350+e | 15 |
| 49 | 36/126 | 1 |
| 50 | 4-amino- | 1 |
| 51 | 4.07-5.22 | 1 |
| 52 | 5,7-dihydroxyflavanone | 1 |
| 53 | 5-aza-2'-deoxycytodine | 1 |
| 54 | 5-malonyl-1,3,4-tricaffeoylquinic | 1 |
| 55 | 500u | 1 |
| 56 | 521873 | 1 |
| 57 | 525797 | 8 |
| 58 | 55/68 | 1 |
| 59 | 57033 | 5 |
| 60 | 58.940 | 1 |
| 61 | 5823 | 2 |
| 62 | 5mgday | 1 |
| 63 | 6/319 | 1 |
| 64 | 60263 | 4 |
| 65 | 60264 | 4 |
| 66 | 64-gy | 1 |
| 67 | 68843 | 1 |
| 68 | 7-glucuronide | 1 |
| 69 | 7.0l/minute | 1 |
| 70 | 72000 | 1 |
| 71 | 75/18.5/200 | 1 |
| 72 | 7npvc | 1 |
| 73 | 8-sulfophenyltheophylline | 2 |
| 74 | 8.8l/minute | 1 |
| 75 | 8x/day | 3 |
| 76 | 9,179 | 1 |
| 77 | =2,6-dimethylphenyl | 1 |
| 78 | abluminal/distal | 1 |
| 79 | ac-kaltghlee-am | 1 |
| 80 | ac-n-buoh-ef- | 1 |
| 81 | accion | 3 |
| 82 | achp | 1 |
| 83 | action- | 1 |
| 84 | acupunctrure | 1 |
| 85 | after1 | 1 |
| 86 | alkaline-activation | 1 |
| 87 | alone | 27,915 |
| 88 | alone.there | 4 |
| 89 | alpha-calcidol | 1 |
| 90 | ambulatoire | 1 |
| 91 | aminohexylgeldanamycin | 1 |
| 92 | aml/arbs | 2 |
| 93 | and/ | 55 |
| 94 | andplacebo | 2 |
| 95 | andsaponins | 1 |
| 96 | anodyne® | 1 |
| 97 | anti-xa-lmwh | 1 |
| 98 | arg-76 | 1 |
| 99 | asp433 | 1 |
| 100 | atpb-rbcl | 1 |
| 101 | aua1 | 1 |
| 102 | augmented-wave | 1 |
| 103 | available-statins | 1 |
| 104 | azatadine | 1 |
| 105 | based-regimen | 2 |
| 106 | basistropfen | 1 |
| 107 | belangeri | 4 |
| 108 | bio-oss® | 2 |
| 109 | bladder-irrigation | 2 |
| 110 | bmpo | 1 |
| 111 | boceprevir- | 1 |
| 112 | caf1 | 1 |
| 113 | casearins | 1 |
| 114 | cba- | 1 |
| 115 | cgp53353 | 3 |
| 116 | cholesytramine | 1 |
| 117 | cispcis-diamminedichloroplatinum | 1 |
| 118 | citrate-midazolam | 1 |
| 119 | cl/ml | 1 |
| 120 | clplhis₆ | 1 |
| 121 | cmfpv | 1 |
| 122 | cocaine-based | 1 |
| 123 | comparisions | 1 |
| 124 | con-only | 1 |
| 125 | coparticipants | 1 |
| 126 | copt1- | 1 |
| 127 | corecontrol® | 1 |
| 128 | critiquing/planning | 1 |
| 129 | crm-carbohydrate | 1 |
| 130 | csa-rad-mp | 1 |
| 131 | curantur | 2 |
| 132 | cyclodestructive | 1 |
| 133 | cystis | 1 |
| 134 | d4t/3tc- | 1 |
| 135 | daunorubicin/ara-c | 1 |
| 136 | dbs/medications | 1 |
| 137 | declizumab | 1 |
| 138 | dehydrobutyrine | 1 |
| 139 | deo | 2 |
| 140 | dermatophagasp | 1 |
| 141 | des-sevo | 1 |
| 142 | dextro-1-methyl-tryptophan | 1 |
| 143 | dic8- | 1 |
| 144 | differentiation/mineralization | 1 |
| 145 | dihydropiridine-preparations | 1 |
| 146 | diolamine | 16 |
| 147 | discontinuation/interruption | 1 |
| 148 | disparting | 1 |
| 149 | dnase/rnase | 1 |
| 150 | docetaxel/doxorubicin | 1 |
| 151 | docetaxel/estramustine | 1 |
| 152 | drophammer | 1 |
| 153 | dyadically | 2 |
| 154 | edisilate | 1 |
| 155 | elvitegravir/ritonavir | 1 |
| 156 | en77 | 1 |
| 157 | enhancer1 | 1 |
| 158 | equiv./l | 2 |
| 159 | esi-negative-ms | 1 |
| 160 | ethinilestradiol | 1 |
| 161 | ethylmethnesulphonate | 1 |
| 162 | extraarticularly | 1 |
| 163 | f-k | 1 |
| 164 | f38 | 1 |
| 165 | fadh | 1 |
| 166 | favipiravir | 1 |
| 167 | ferumoxtyol | 1 |
| 168 | fluoexetine | 1 |
| 169 | folfiri.3 | 1 |
| 170 | formigenes | 6 |
| 171 | formingenes | 1 |
| 172 | fst-ul | 1 |
| 173 | ftc/zidovudine/efavirenz | 1 |
| 174 | ga-bao | 2 |
| 175 | gartner | 1 |
| 176 | gelatin- | 1 |
| 177 | gentacicol | 1 |
| 178 | gii.13 | 1 |
| 179 | gmfad7-1 | 1 |
| 180 | gpo® | 1 |
| 181 | gramine | 1 |
| 182 | group-£2,171 | 1 |
| 183 | group=76 | 1 |
| 184 | gsk4716 | 1 |
| 185 | guided-therapy | 2 |
| 186 | hemocytometry | 3 |
| 187 | hib-specific | 1 |
| 188 | high-igg | 2 |
| 189 | hindfoot-ankle | 1 |
| 190 | hla-b*44:02g | 1 |
| 191 | hyperuremia | 1 |
| 192 | hypo/hyperglycemia-mitigation | 1 |
| 193 | ic.04-12 | 2 |
| 194 | ii-antialdosterones | 1 |
| 195 | immunolymphoscintigraphy | 1 |
| 196 | immunosuppresant | 1 |
| 197 | implicity | 1 |
| 198 | inamd | 1 |
| 199 | inattentively | 1 |
| 200 | inclusive/parallel | 1 |
| 201 | indistinctively | 1 |
| 202 | initiated.3 | 1 |
| 203 | initiation≥10ml/min/1.73m | 1 |
| 204 | insigs | 1 |
| 205 | instruction-a | 1 |
| 206 | inter-changeably | 2 |
| 207 | internal/autonomous | 1 |
| 208 | intraarticulary | 2 |
| 209 | intrapartum- | 1 |
| 210 | intratumorly | 1 |
| 211 | iomri-guided | 1 |
| 212 | isethionate | 14 |
| 213 | isotonic- | 1 |
| 214 | kisspeptins | 1 |
| 215 | krabok | 1 |
| 216 | laba/lama/ics | 1 |
| 217 | lactantes | 5 |
| 218 | laryngoscopy-guided | 1 |
| 219 | layer-3 | 1 |
| 220 | levo-adrenaline | 1 |
| 221 | lipofacton | 1 |
| 222 | lm- | 1 |
| 223 | loratadine/montelukast | 1 |
| 224 | lsa2l2-type | 1 |
| 225 | macushield | 1 |
| 226 | medium-acting | 1 |
| 227 | merbarone | 1 |
| 228 | mesostable | 1 |
| 229 | methanethiosulfonate-ethylammonium | 1 |
| 230 | mg-aspartate-hydrochloride | 1 |
| 231 | misadministrations | 1 |
| 232 | misconceptions/misunderstandings | 1 |
| 233 | motor-level | 1 |
| 234 | mscbt | 1 |
| 235 | n-acetyl-l-carnitine | 1 |
| 236 | negative-sad | 1 |
| 237 | no-pv | 1 |
| 238 | no-wup | 1 |
| 239 | no711 | 1 |
| 240 | non-complaint | 1 |
| 241 | non-dipper-type | 1 |
| 242 | non-teacher | 1 |
| 243 | nonsense/splicing | 1 |
| 244 | nr1a/nr2a | 1 |
| 245 | nurse-peer | 1 |
| 246 | nxy-058 | 2 |
| 247 | obese-resistant | 1 |
| 248 | omstreken | 1 |
| 249 | opbe | 1 |
| 250 | options-extraction | 1 |
| 251 | orange® | 2 |
| 252 | overdraw | 1 |
| 253 | p-cymene/β-cyclodextrin | 1 |
| 254 | p42a | 2 |
| 255 | pagaptanbib | 1 |
| 256 | parodontocid | 2 |
| 257 | parvastatin | 1 |
| 258 | peg-3350 | 17 |
| 259 | pentafluorophenylhydrazine | 1 |
| 260 | perfluoroalkoxy | 1 |
| 261 | perfusion-cooling | 1 |
| 262 | pgp-4008 | 2 |
| 263 | phenylglycoside | 1 |
| 264 | pl-20 | 4 |
| 265 | placarbil | 9 |
| 266 | placeo | 1 |
| 267 | plus-j | 3 |
| 268 | poly-l-lysines | 3 |
| 269 | polyhexamethylene-biguanide | 1 |
| 270 | polystyrene-co-divinylbenzene | 1 |
| 271 | porpouses | 1 |
| 272 | postmenopausally | 4 |
| 273 | processibility | 1 |
| 274 | propofol/fentanyl/dexmedetomidine | 1 |
| 275 | prp-augmented | 1 |
| 276 | pulsatile- | 1 |
| 277 | pursuit-direction | 1 |
| 278 | q-8h | 1 |
| 279 | q15l | 2 |
| 280 | quercetin-3-o-β-d-glucopyranosil | 1 |
| 281 | r-467 | 1 |
| 282 | redita | 1 |
| 283 | remifentanil-atropine | 1 |
| 284 | repinotan | 1 |
| 285 | retard® | 1 |
| 286 | riba-positive | 1 |
| 287 | risedronate- | 1 |
| 288 | rituximab-chop | 1 |
| 289 | rm+sm | 1 |
| 290 | rr1.10 | 1 |
| 291 | s.r.l. | 3 |
| 292 | score-original | 1 |
| 293 | self-mixed | 2 |
| 294 | single-ζ | 1 |
| 295 | siramesine | 1 |
| 296 | sodium-diatrizoate | 1 |
| 297 | spheroidene/spheroidenone | 1 |
| 298 | spico | 1 |
| 299 | stami | 1 |
| 300 | study-05 | 1 |
| 301 | study.it | 1 |
| 302 | succinate/glutamate | 1 |
| 303 | survey/enquete | 1 |
| 304 | system1 | 1 |
| 305 | system® | 9 |
| 306 | technology™ | 1 |
| 307 | tg1306/1r | 1 |
| 308 | thio-barbituric-acid-reacting-substances | 1 |
| 309 | thiobarbituric-acid-reactive-substances | 1 |
| 310 | threat-alleviating | 1 |
| 311 | thu | 1 |
| 312 | til/il-2 | 1 |
| 313 | time-rtt | 1 |
| 314 | time/resident/day | 2 |
| 315 | tinture | 1 |
| 316 | tnf-α-inhibitors | 1 |
| 317 | tpbp | 1 |
| 318 | treated-aparasitaemic | 1 |
| 319 | treated-parasitaemic | 1 |
| 320 | twice/year | 1 |
| 321 | un-supplemented | 1 |
| 322 | under-perceivers | 1 |
| 323 | ura3 | 1 |
| 324 | vancomycin/cefepime | 1 |
| 325 | vri-iv | 1 |
| 326 | wg-rich | 1 |
| 327 | wheat-barley-rye- | 1 |
| 328 | whitei | 11 |
| 329 | whytei | 1 |
| 330 | wideness | 2 |
| 331 | will:1 | 1 |
| 332 | work-package | 1 |
| 333 | work-they | 1 |
| 334 | xbk1 | 1 |
| 335 | xefocame | 1 |
| 336 | xk1 | 2 |
| 337 | y-690 | 1 |
| 338 | yfh1-isu | 1 |
| 339 | yo8 | 1 |
| 340 | z-asp-ch | 1 |
| 341 | €18,957 | 1 |
| 342 | €3636 | 1 |
| 343 | ≤20/40 | 3 |
| 344 | ≤30min | 1 |
| 345 | ≥1.020 | 1 |
| 1 | 10/10- | 1 |
| 2 | copt1- | 1 |
| 3 | dic8- | 1 |
| 4 | cba- | 1 |
| 5 | isotonic- | 1 |
| 6 | d4t/3tc- | 1 |
| 7 | pulsatile- | 1 |
| 8 | risedronate- | 1 |
| 9 | wheat-barley-rye- | 1 |
| 10 | ac-n-buoh-ef- | 1 |
| 11 | lm- | 1 |
| 12 | intrapartum- | 1 |
| 13 | gelatin- | 1 |
| 14 | action- | 1 |
| 15 | 4-amino- | 1 |
| 16 | boceprevir- | 1 |
| 17 | 1½- | 1 |
| 18 | s.r.l. | 3 |
| 19 | and/ | 55 |
| 20 | 72000 | 1 |
| 21 | 75/18.5/200 | 1 |
| 22 | rr1.10 | 1 |
| 23 | pl-20 | 4 |
| 24 | ≥1.020 | 1 |
| 25 | ≤20/40 | 3 |
| 26 | 58.940 | 1 |
| 27 | peg-3350 | 17 |
| 28 | 2.5/80 | 1 |
| 29 | y-690 | 1 |
| 30 | 12457-1 | 1 |
| 31 | gmfad7-1 | 1 |
| 32 | no711 | 1 |
| 33 | group-£2,171 | 1 |
| 34 | 1201081 | 3 |
| 35 | 12791 | 5 |
| 36 | will:1 | 1 |
| 37 | aua1 | 1 |
| 38 | caf1 | 1 |
| 39 | xbk1 | 1 |
| 40 | xk1 | 2 |
| 41 | system1 | 1 |
| 42 | enhancer1 | 1 |
| 43 | after1 | 1 |
| 44 | 12457-2 | 1 |
| 45 | til/il-2 | 1 |
| 46 | ic.04-12 | 2 |
| 47 | 4.07-5.22 | 1 |
| 48 | 122/282 | 1 |
| 49 | layer-3 | 1 |
| 50 | initiated.3 | 1 |
| 51 | folfiri.3 | 1 |
| 52 | gii.13 | 1 |
| 53 | 5823 | 2 |
| 54 | 3.75-5.33 | 1 |
| 55 | 57033 | 5 |
| 56 | asp433 | 1 |
| 57 | 68843 | 1 |
| 58 | cgp53353 | 3 |
| 59 | 60263 | 4 |
| 60 | 521873 | 1 |
| 61 | 282-383 | 1 |
| 62 | ura3 | 1 |
| 63 | 129/704 | 1 |
| 64 | 60264 | 4 |
| 65 | 1:0.5 | 2 |
| 66 | study-05 | 1 |
| 67 | 0/85 | 1 |
| 68 | gsk4716 | 1 |
| 69 | 36/126 | 1 |
| 70 | 124:2422-2426 | 1 |
| 71 | €3636 | 1 |
| 72 | 2.38-2.56 | 1 |
| 73 | arg-76 | 1 |
| 74 | group=76 | 1 |
| 75 | €18,957 | 1 |
| 76 | r-467 | 1 |
| 77 | en77 | 1 |
| 78 | 2.32-2.87 | 1 |
| 79 | 525797 | 8 |
| 80 | pgp-4008 | 2 |
| 81 | f38 | 1 |
| 82 | nxy-058 | 2 |
| 83 | 55/68 | 1 |
| 84 | yo8 | 1 |
| 85 | +42.9 | 1 |
| 86 | 20+/-7.9 | 1 |
| 87 | 6/319 | 1 |
| 88 | 9,179 | 1 |
| 89 | instruction-a | 1 |
| 90 | 301a | 1 |
| 91 | -ifna-2a | 1 |
| 92 | p42a | 2 |
| 93 | nr1a/nr2a | 1 |
| 94 | hyperuremia | 1 |
| 95 | +beta | 1 |
| 96 | redita | 1 |
| 97 | 2b-4b | 2 |
| 98 | declizumab | 1 |
| 99 | pagaptanbib | 1 |
| 100 | daunorubicin/ara-c | 1 |
| 101 | hib-specific | 1 |
| 102 | treated-parasitaemic | 1 |
| 103 | treated-aparasitaemic | 1 |
| 104 | 5-malonyl-1,3,4-tricaffeoylquinic | 1 |
| 105 | 7npvc | 1 |
| 106 | 250mg/d | 1 |
| 107 | 0.5mg/d | 4 |
| 108 | negative-sad | 1 |
| 109 | iomri-guided | 1 |
| 110 | laryngoscopy-guided | 1 |
| 111 | cocaine-based | 1 |
| 112 | un-supplemented | 1 |
| 113 | prp-augmented | 1 |
| 114 | self-mixed | 2 |
| 115 | parodontocid | 2 |
| 116 | macushield | 1 |
| 117 | inamd | 1 |
| 118 | 3350+e | 15 |
| 119 | opbe | 1 |
| 120 | 2-chloroethyl-ethylsulfide | 1 |
| 121 | polyhexamethylene-biguanide | 1 |
| 122 | 7-glucuronide | 1 |
| 123 | mg-aspartate-hydrochloride | 1 |
| 124 | phenylglycoside | 1 |
| 125 | 3-sambubioside | 1 |
| 126 | work-package | 1 |
| 127 | mesostable | 1 |
| 128 | hindfoot-ankle | 1 |
| 129 | xefocame | 1 |
| 130 | vancomycin/cefepime | 1 |
| 131 | polystyrene-co-divinylbenzene | 1 |
| 132 | azatadine | 1 |
| 133 | propofol/fentanyl/dexmedetomidine | 1 |
| 134 | 5-aza-2'-deoxycytodine | 1 |
| 135 | levo-adrenaline | 1 |
| 136 | 8-sulfophenyltheophylline | 2 |
| 137 | diolamine | 16 |
| 138 | gramine | 1 |
| 139 | cholesytramine | 1 |
| 140 | 2-aminoadenine | 1 |
| 141 | remifentanil-atropine | 1 |
| 142 | dehydrobutyrine | 1 |
| 143 | siramesine | 1 |
| 144 | fluoexetine | 1 |
| 145 | n-acetyl-l-carnitine | 1 |
| 146 | docetaxel/estramustine | 1 |
| 147 | pentafluorophenylhydrazine | 1 |
| 148 | alone | 27,915 |
| 149 | 5,7-dihydroxyflavanone | 1 |
| 150 | spheroidene/spheroidenone | 1 |
| 151 | merbarone | 1 |
| 152 | lsa2l2-type | 1 |
| 153 | non-dipper-type | 1 |
| 154 | alone.there | 4 |
| 155 | ambulatoire | 1 |
| 156 | acupunctrure | 1 |
| 157 | tinture | 1 |
| 158 | dnase/rnase | 1 |
| 159 | edisilate | 1 |
| 160 | succinate/glutamate | 1 |
| 161 | 2-aminoethyldiphenylborinate | 1 |
| 162 | ethylmethnesulphonate | 1 |
| 163 | isethionate | 14 |
| 164 | sodium-diatrizoate | 1 |
| 165 | crm-carbohydrate | 1 |
| 166 | survey/enquete | 1 |
| 167 | 7.0l/minute | 1 |
| 168 | 8.8l/minute | 1 |
| 169 | augmented-wave | 1 |
| 170 | cyclodestructive | 1 |
| 171 | riba-positive | 1 |
| 172 | -bg-csf | 1 |
| 173 | hla-b*44:02g | 1 |
| 174 | 1x3g | 1 |
| 175 | high-igg | 2 |
| 176 | 10/20-mg | 1 |
| 177 | 3000mg | 1 |
| 178 | 10/40mg | 1 |
| 179 | nonsense/splicing | 1 |
| 180 | perfusion-cooling | 1 |
| 181 | critiquing/planning | 1 |
| 182 | threat-alleviating | 1 |
| 183 | medium-acting | 1 |
| 184 | disparting | 1 |
| 185 | 18μg | 1 |
| 186 | q-8h | 1 |
| 187 | z-asp-ch | 1 |
| 188 | wg-rich | 1 |
| 189 | fadh | 1 |
| 190 | anti-xa-lmwh | 1 |
| 191 | whitei | 11 |
| 192 | whytei | 1 |
| 193 | stami | 1 |
| 194 | belangeri | 4 |
| 195 | plus-j | 3 |
| 196 | f-k | 1 |
| 197 | 1×week | 1 |
| 198 | krabok | 1 |
| 199 | equiv./l | 2 |
| 200 | q15l | 2 |
| 201 | 3-hydroxy-2-methylpentanal | 1 |
| 202 | score-original | 1 |
| 203 | abluminal/distal | 1 |
| 204 | atpb-rbcl | 1 |
| 205 | inclusive/parallel | 1 |
| 206 | motor-level | 1 |
| 207 | 32.6gl | 1 |
| 208 | placarbil | 9 |
| 209 | quercetin-3-o-β-d-glucopyranosil | 1 |
| 210 | cl/ml | 1 |
| 211 | gentacicol | 1 |
| 212 | alpha-calcidol | 1 |
| 213 | ethinilestradiol | 1 |
| 214 | ferumoxtyol | 1 |
| 215 | fst-ul | 1 |
| 216 | =2,6-dimethylphenyl | 1 |
| 217 | 1,4-diethynylphenyl | 1 |
| 218 | initiation≥10ml/min/1.73m | 1 |
| 219 | ac-kaltghlee-am | 1 |
| 220 | citrate-midazolam | 1 |
| 221 | rm+sm | 1 |
| 222 | methanethiosulfonate-ethylammonium | 1 |
| 223 | cispcis-diamminedichloroplatinum | 1 |
| 224 | dextro-1-methyl-tryptophan | 1 |
| 225 | 2,4-diacyl-2,3-dihydrofuran | 1 |
| 226 | repinotan | 1 |
| 227 | basistropfen | 1 |
| 228 | omstreken | 1 |
| 229 | based-regimen | 2 |
| 230 | docetaxel/doxorubicin | 1 |
| 231 | aminohexylgeldanamycin | 1 |
| 232 | ≤30min | 1 |
| 233 | p-cymene/β-cyclodextrin | 1 |
| 234 | +guaiphenesin | 1 |
| 235 | parvastatin | 1 |
| 236 | accion | 3 |
| 237 | bladder-irrigation | 2 |
| 238 | hypo/hyperglycemia-mitigation | 1 |
| 239 | alkaline-activation | 1 |
| 240 | differentiation/mineralization | 1 |
| 241 | options-extraction | 1 |
| 242 | pursuit-direction | 1 |
| 243 | discontinuation/interruption | 1 |
| 244 | lipofacton | 1 |
| 245 | ga-bao | 2 |
| 246 | andplacebo | 2 |
| 247 | spico | 1 |
| 248 | placeo | 1 |
| 249 | deo | 2 |
| 250 | bmpo | 1 |
| 251 | des-sevo | 1 |
| 252 | tpbp | 1 |
| 253 | achp | 1 |
| 254 | csa-rad-mp | 1 |
| 255 | rituximab-chop | 1 |
| 256 | dermatophagasp | 1 |
| 257 | no-wup | 1 |
| 258 | tg1306/1r | 1 |
| 259 | 2r→3r | 2 |
| 260 | twice/year | 1 |
| 261 | nurse-peer | 1 |
| 262 | non-teacher | 1 |
| 263 | drophammer | 1 |
| 264 | gartner | 1 |
| 265 | elvitegravir/ritonavir | 1 |
| 266 | favipiravir | 1 |
| 267 | curantur | 2 |
| 268 | aml/arbs | 2 |
| 269 | laba/lama/ics | 1 |
| 270 | thiobarbituric-acid-reactive-substances | 1 |
| 271 | thio-barbituric-acid-reacting-substances | 1 |
| 272 | 20-nucleotides | 1 |
| 273 | formigenes | 6 |
| 274 | formingenes | 1 |
| 275 | poly-l-lysines | 3 |
| 276 | ii-antialdosterones | 1 |
| 277 | porpouses | 1 |
| 278 | lactantes | 5 |
| 279 | insigs | 1 |
| 280 | misconceptions/misunderstandings | 1 |
| 281 | cystis | 1 |
| 282 | 0.4-ms | 1 |
| 283 | esi-negative-ms | 1 |
| 284 | andsaponins | 1 |
| 285 | casearins | 1 |
| 286 | available-statins | 1 |
| 287 | kisspeptins | 1 |
| 288 | comparisions | 1 |
| 289 | dbs/medications | 1 |
| 290 | dihydropiridine-preparations | 1 |
| 291 | misadministrations | 1 |
| 292 | under-perceivers | 1 |
| 293 | tnf-α-inhibitors | 1 |
| 294 | wideness | 2 |
| 295 | coparticipants | 1 |
| 296 | internal/autonomous | 1 |
| 297 | mscbt | 1 |
| 298 | study.it | 1 |
| 299 | immunosuppresant | 1 |
| 300 | obese-resistant | 1 |
| 301 | non-complaint | 1 |
| 302 | loratadine/montelukast | 1 |
| 303 | time-rtt | 1 |
| 304 | 24i.u | 1 |
| 305 | 500u | 1 |
| 306 | thu | 1 |
| 307 | yfh1-isu | 1 |
| 308 | 2b/rbv | 1 |
| 309 | vri-iv | 1 |
| 310 | no-pv | 1 |
| 311 | cmfpv | 1 |
| 312 | overdraw | 1 |
| 313 | 0.5mg/day | 1 |
| 314 | time/resident/day | 2 |
| 315 | 8x/day | 3 |
| 316 | 5mgday | 1 |
| 317 | work-they | 1 |
| 318 | 64-gy | 1 |
| 319 | immunolymphoscintigraphy | 1 |
| 320 | inter-changeably | 2 |
| 321 | indistinctively | 1 |
| 322 | inattentively | 1 |
| 323 | dyadically | 2 |
| 324 | postmenopausally | 4 |
| 325 | con-only | 1 |
| 326 | extraarticularly | 1 |
| 327 | intratumorly | 1 |
| 328 | guided-therapy | 2 |
| 329 | intraarticulary | 2 |
| 330 | hemocytometry | 3 |
| 331 | implicity | 1 |
| 332 | processibility | 1 |
| 333 | perfluoroalkoxy | 1 |
| 334 | ftc/zidovudine/efavirenz | 1 |
| 335 | clplhis₆ | 1 |
| 336 | technology™ | 1 |
| 337 | retard® | 1 |
| 338 | orange® | 2 |
| 339 | anodyne® | 1 |
| 340 | corecontrol® | 1 |
| 341 | system® | 9 |
| 342 | gpo® | 1 |
| 343 | bio-oss® | 2 |
| 344 | 100mg/m² | 1 |
| 345 | single-ζ | 1 |